BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21811091)

  • 1. Nelfinavir induces radiation sensitization in pituitary adenoma cells.
    Zeng J; See AP; Aziz K; Thiyagarajan S; Salih T; Gajula RP; Armour M; Phallen J; Terezakis S; Kleinberg L; Redmond K; Hales RK; Salvatori R; Quinones-Hinojosa A; Tran PT; Lim M
    Cancer Biol Ther; 2011 Oct; 12(7):657-63. PubMed ID: 21811091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
    Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
    Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors.
    Chanal M; Chevallier P; Raverot V; Fonteneau G; Lucia K; Monteserin Garcia JL; Rachwan A; Jouanneau E; Trouillas J; Honnorat J; Auger C; Theodoropoulou M; Raverot G
    Mol Cancer Ther; 2016 Jun; 15(6):1261-70. PubMed ID: 26983879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lncRNA HULC knockdown on rat secreting pituitary adenoma GH3 cells.
    Rui QH; Ma JB; Liao YF; Dai JH; Cai ZY
    Braz J Med Biol Res; 2019; 52(4):e7728. PubMed ID: 30994730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas.
    Monsalves E; Juraschka K; Tateno T; Agnihotri S; Asa SL; Ezzat S; Zadeh G
    Endocr Relat Cancer; 2014 Aug; 21(4):R331-44. PubMed ID: 25052915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
    Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
    Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thioridazine Sensitizes Esophageal Carcinoma Cell Lines to Radiotherapy-Induced Apoptosis In Vitro and In Vivo.
    Li H; Juan L; Xia L; Wang Y; Bao Y; Sun G
    Med Sci Monit; 2016 Jul; 22():2624-34. PubMed ID: 27453171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Celastrol Induces Apoptosis and Autophagy via the AKT/mTOR Signaling Pathway in the Pituitary ACTH-secreting Adenoma Cells.
    Cai Z; Qian B; Pang J; Tan ZB; Zhao K; Lei T
    Curr Med Sci; 2022 Apr; 42(2):387-396. PubMed ID: 35419676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo.
    Liu Y; Cui B; Qiao Y; Zhang Y; Tian Y; Jiang J; Ma D; Kong B
    Int J Gynecol Cancer; 2011 Jan; 21(1):100-5. PubMed ID: 21330835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyphyllin I Promoted Melanoma Cells Autophagy and Apoptosis via PI3K/Akt/mTOR Signaling Pathway.
    Long J; Pi X
    Biomed Res Int; 2020; 2020():5149417. PubMed ID: 32733943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
    Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB
    Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
    Kimple RJ; Vaseva AV; Cox AD; Baerman KM; Calvo BF; Tepper JE; Shields JM; Sartor CI
    Clin Cancer Res; 2010 Feb; 16(3):912-23. PubMed ID: 20103665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer.
    Chen YH; Wei MF; Wang CW; Lee HW; Pan SL; Gao M; Kuo SH; Cheng AL; Teng CM
    Cancer Lett; 2015 Feb; 357(2):582-90. PubMed ID: 25497009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway.
    Chen S; Yao L
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):323-334. PubMed ID: 33978839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AFAP1-AS1 Promotes Proliferation of Pituitary Adenoma Cells through miR-103a-3p to Activate PI3K/AKT Signaling Pathway.
    Tang H; Zhu D; Zhang G; Luo X; Xie W
    World Neurosurg; 2019 Oct; 130():e888-e898. PubMed ID: 31299308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
    Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
    Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of p27 sensitize to dual PI3K/mTOR inhibition.
    Lee M; Theodoropoulou M; Graw J; Roncaroli F; Zatelli MC; Pellegata NS
    Mol Cancer Ther; 2011 Aug; 10(8):1450-9. PubMed ID: 21646547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway.
    Zhou J; Jiang YY; Chen H; Wu YC; Zhang L
    Cell Prolif; 2020 Feb; 53(2):e12739. PubMed ID: 31820522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K/Akt/mTOR pathway involvement in regulating growth hormone secretion in a rat pituitary adenoma cell line.
    Di Pasquale C; Gentilin E; Falletta S; Bellio M; Buratto M; Degli Uberti E; Chiara Zatelli M
    Endocrine; 2018 May; 60(2):308-316. PubMed ID: 29080043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
    Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
    Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.